drugset / Trial / NCT02788513
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.
Timeline
- Start
- 2016-08-11
- Primary completion
- 2019-09-12
- Completion
- 2019-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iclepertin | Small molecule | 2 mg | Oral |
| Subject | Iclepertin | Small molecule | 5 mg | Oral |
| Subject | Iclepertin | Small molecule | 10 mg | Oral |
| Subject | Iclepertin | Small molecule | 25 mg | Oral |